[<sup>111</sup>In]In/[<sup>177</sup>Lu]Lu-AAZTA<sup>5</sup>-LM4 SST<sub>2</sub>R-Antagonists in Cancer Theranostics: From Preclinical Testing to First Patient Results
Aiming to expand the application of the SST<sub>2</sub>R-antagonist LM4 (DPhe-c[DCys-4Pal-DAph(Cbm)-Lys-Thr-Cys]-DTyr-NH<sub>2</sub>) beyond [<sup>68</sup>Ga]Ga-DATA<sup>5m</sup>-LM4 PET/CT (DATA<sup>5m</sup>, (6-pentanoic acid)-6-(amino)me...
Saved in:
Main Authors: | Berthold A. Nock (Author), Panagiotis Kanellopoulos (Author), Euy Sung Moon (Author), Maritina Rouchota (Author), George Loudos (Author), Sanjana Ballal (Author), Madhav P. Yadav (Author), Chandrasekhar Bal (Author), Prashant Mishra (Author), Parvind Sheokand (Author), Frank Roesch (Author), Theodosia Maina (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [<sup>177</sup>Lu]Lu-DOTA.SA.FAPi and [<sup>177</sup>Lu]Lu-DOTAGA.(SA.FAPi)<sub>2</sub>
by: Sanjana Ballal, et al.
Published: (2021) -
Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [<sup>177</sup>Lu]Lu-Satoreotide Tetraxetan and the Agonist [<sup>177</sup>Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST<sub>2</sub>-Positive Tumours
by: Pascale Plas, et al.
Published: (2022) -
One Step Closer to Clinical Translation: Enhanced Tumor Targeting of [<sup>99m</sup>Tc]Tc-DB4 and [<sup>111</sup>In]In-SG4 in Mice Treated with Entresto
by: Panagiotis Kanellopoulos, et al.
Published: (2020) -
[<sup>177</sup>Lu]Lu-PSMA-617 (Pluvicto<sup>TM</sup>): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer
by: Ute Hennrich, et al.
Published: (2022) -
Therapeutic Potential of <sup>47</sup>Sc in Comparison to <sup>177</sup>Lu and <sup>90</sup>Y: Preclinical Investigations
by: Klaudia Siwowska, et al.
Published: (2019)